Why the study?
Does mibefradil improve blood pressure and anginal symptoms in patients with hypertension and chronic stable angina compared to other calcium-channel antagonists?
Population
Patients with hypertension and chronic stable angina pectoris
Comparison
Mibefradil 50 or 100 mg once daily vs Other calcium-channel antagonists
Design
Review
Authors
Loading...
Supports mibefradil for hypertension and angina versus select CCBs; leaves open its role versus contemporary agents in prospective trials.
Does mibefradil improve blood pressure and anginal symptoms in patients with hypertension and chronic stable angina compared to other calcium-channel antagonists?
Mibefradil is a novel T-type calcium channel antagonist that effectively treats hypertension and chronic stable angina without causing negative inotropy or reflex tachycardia.
Billups et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: